A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent

Summary.  Background:  The REG2 anticoagulation system consists of pegnivacogin, a subcutaneously administered aptamer factor IXa inhibitor, and its intravenous control agent, anivamersen. Objectives:  To assess the safety, tolerability and pharmacokinetic and pharmacodynamic responses of REG2. Patients/Methods:  In this phase 1a study, 36 healthy volunteers were enrolled into five cohorts and given one dose of pegnivacogin. Cohorts 1 ( n  = 6) and 1A ( n  = 4) received 0.5 mg kg −1 ; cohort 2 ( n  = 6) received 1.0 mg kg −1 ; cohort 3 ( n  = 6) received 3.0 mg kg −1 ; and cohort 4 ( n  = 8) received 2.0 mg kg −1 . In cohorts 1–3, two subjects were randomized to placebo. Cohort 4 subjects were subsequently randomized to single‐dose ( n  = 4) or multidose ( n  = 4) anivamersen. Results:  The mean maximum observed concentrations of pegnivacogin in cohorts 1, 1A, 2 and 3 at median time were 5.16 μg mL −1 at 84 h, 5.19 μg mL −1 at 72 h, 9.32 μg mL −1 at 90 h, and 32.5 μg mL −1 at 84 h, respectively. The maximum relative activated partial thromboplastin time and time needed to achieve this were 1.18 at 2 days, 1.16 at 2 days, 1.27 at 3 days, and 1.85 at 2 days, respectively. The calculated mean half‐life and mean residence times of pegnivacogin were 6.12 days and 9.6 days, respectively. There was rapid reversal with intravenous anivamersen, although subsequent reaccumulation of pegnivacogin was observed. Conclusions:  In our first‐in‐human study, REG2 was well tolerated and provided dose‐proportional anticoagulation for several days after a single subcutaneous dose, with complete, although transient, reversal by its control agent. This study demonstrates the first application of a subcutaneously administered aptamer, and represents a potential advance in aptamer therapeutics.